Omni Bio to Present at Biotech Showcase 2015
(firmenpresse) - FORT COLLINS, CO -- (Marketwired) -- 01/06/15 -- (OTC PINK: OMBP) ("Omni Bio"), an emerging biopharmaceutical company focused on revolutionizing the treatment of immune-mediated inflammatory diseases, announced today that the Company is scheduled to present at the Biotech Showcase™ 2015 meeting taking place in San Francisco, CA on January 12-14, 2015.
Bruce Schneider, Ph.D., Chief Executive Officer of Omni Bio, will provide an overview of the Company's business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. Meetings with management may also be scheduled outside of Biotech Showcase by contacting Omni Bio's investor relations partner.
Tuesday, January 13, 2015
3:30 pm (Pacific Time)
Parc 55 Wyndham, San Francisco, CA
The Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this critical week, which is widely viewed as setting the tone for the coming year.
Omni Bio Pharmaceutical, Inc. ("Omni Bio") is an emerging biopharmaceutical company focused on revolutionizing the treatment of immune-mediated inflammatory disease. The Company's technology platform, AAT-Fc, is a recombinant version of plasma-derived alpha-1 antitrypsin (p-AAT), a naturally occurring human protein that is currently commercialized as an intravenous supplementation therapy for AAT-deficient individuals. Omni Bio seeks to capitalize on emerging scientific evidence of AAT's fundamental role in mediating multiple anti-inflammatory and tissue protective pathways by developing first-in-class therapeutics to address a broad array of new clinical opportunities.
Omni Bio's recombinant AAT-Fc can offer several potential advantages over current p-AAT products, including superior potency, longer half-life, improved safety and easy-to-administer subcutaneous dosing, as well as significantly enhanced manufacturing scalability. Omni Bio intends to exploit AAT-Fc's enhanced product potential to address multiple, high-value immune-mediated inflammatory disease indications, such as Type 1 diabetes, graft versus host disease and chronic gout. The Company holds broad intellectual property covering both recombinant and plasma-derived AAT for these and other indications.
For more information, please visit .
This press release contains forward-looking statements that reflect the Company's current expectations as of the date of this press release, and involve certain risks and uncertainties that could cause actual results to differ materially from those anticipated in these forward-looking statements. Factors that could cause future results to materially differ from forward-looking statements include the risks described in Omni Bio Pharmaceutical, Inc.'s Form 10-K for the fiscal year ended March 31, 2014 and other reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements. The Company's further development is highly dependent on raising capital to support its activities, future medical and research developments and market acceptance, and other risks that are outside of the Company's control.
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D.
(Investors)
(212) 375-2664
Amy Wheeler
(Media)
(646) 362-5750
Omni Bio Pharmaceuticals, Inc.
(970) 237-5178
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 06.01.2015 - 14:00 Uhr
Sprache: Deutsch
News-ID 362530
Anzahl Zeichen: 5762
contact information:
Town:
FORT COLLINS, CO
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 224 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Omni Bio to Present at Biotech Showcase 2015"
steht unter der journalistisch-redaktionellen Verantwortung von
Omni Bio Pharmaceutical, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
